Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium.

Presentation Details

Date: Thursday, July 9, 2026
Time: 2:30 p.m. Eastern Daylight Time
Live Presentation: Available on Kiora's Investor Relations homepage at ir.kiorapharma.com
Replay: Available for 90 days on Kiora's Investor Relations Events page at ir.kiorapharma.com/news-events/events

About Kiora Pharmaceuticals

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed initially for the treatment of retinitis pigmentosa, with potential to expand into choroideremia and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of macular edema due to retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).

In addition to news releases and SEC filings, we expect to post information on our website, https://www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303675

SOURCE Kiora Pharmaceuticals, Inc.

Released July 2, 2026